EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD38 , CD39 , and BCL2 differentiate disseminated forms of high‐grade B‐cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B‐cell lymphoma

Pauline Marianini, Vanessa Lacheretz-Szablewski, Marion Almeras, Jérôme Moreaux iD, Caroline Bret iD

Cytometry Part B: Clinical Cytometry · 2024-11 · 106 (6) · 448-464

DOI: 10.1002/cyto.b.22208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, online erschienen am 19.09.2024. Verfasst von Pauline Marianini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Hematology, St Eloi Hospital, Montpellier University Hospital, Montpellier, France. Hauptthemen laut MEDLINE: Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-bcl-2, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de la Recherche, Institut National Du Cancer, PLBIO22 PICASO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐grade B‐cell lymphomas (HGBCL) represent a heterogeneous group of very rare mature B‐cell lymphomas. The 4th revised edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (WHO‐HAEM) previously defined two categories of HGBCL: the so‐called double‐hit (DHL) and triple‐hit (THL) lymphomas, which were related to forms harboring MYC and BCL2 and/or BCL6 rearrangements, and HGBCL, NOS (not otherwise specified), corresponding to entities with intermediate characteristics between diffuse large B‐cell lymphoma (DLBCL) and Burkitt lymphoma (BL), without rearrangement of the MYC and BCL2 , and/or BCL6 genes. In the 5th edition of the WHO‐HAEM, DHL with MYC and BCL2 rearrangements or THL were reassigned as DLBCL/HGBCL with MYC and BCL2 rearrangements (DLBCL/HGBL‐ MYC / BCL2 ), whereas the category HGBCL, NOS remains unchanged. Characterized by an aggressive clinical presentation and a poor prognosis, HGBCL is often diagnosed at an advanced, widespread stage, leading to potential disseminated forms with a leukemic presentation, or spreading to the bone marrow (BM) or other biological fluids. Flow cytometric immunophenotypic study of these disseminated cells can provide a rapid method to identify HGBCL. However, due to the scarcity of cases, only limited data about the immunophenotypic features of HGBCL by multiparametric flow cytometry are available. In addition, identification of HGBCL cells by this technique may be challenging due to clinical, pathological, and biological features that can overlap with other distinct lymphoid malignancies, including Burkitt lymphoma (BL), diffuse large B‐cell lymphoma (DLBCL), and even B acute lymphoblastic leukemia (B‐ALL). In this study, we aimed to characterize the detailed immunophenotypic portrait of HGBCL, evaluating by multiparametric flow cytometry (MFC) the expression of 26 markers on biological samples obtained from a cohort of 10 newly‐diagnosed cases and comparing their level of expression with normal peripheral blood (PB) B lymphocytes ( n = 10 samples), tumoral cells from patients diagnosed with B‐ALL ( n = 30), BL ( n = 13), or DLBCL ( n = 22). We then proposed a new and simple approach to rapidly distinguish disseminated forms of HGBCL, BL, and DLBCL, using the combination of MFC data for CD38, BCL2, and CD39, the three most discriminative markers explored in this study. We finally confirmed the utility of the scoring system previously proposed by Khanlari to distinguish HGBCL cells from B lymphoblasts of B‐ALL. In conclusion, we described a distinct immunophenotypic portrait of HGBCL cells and proposed a strategy to differentiate these cells from other aggressive B lymphoma entities in biological samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Burkitt LymphomaLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2ADP-ribosyl Cyclase 1HumansMaleFemaleMiddle AgedAdultAgedImmunophenotypingBiomarkers, TumorAged, 80 and overFlow CytometryDiagnosis, DifferentialYoung Adult

Stichwörter der Autor:innen

BCL2CD38CD39high grade B cell lymphomasmulticolor flow cytometry

Substanzen

Proto-Oncogene Proteins c-bcl-2BCL2 protein, humanADP-ribosyl Cyclase 1Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Biological Hematology, St Eloi Hospital, Montpellier University Hospital, Montpellier, France.
  • Department of Pathology and Onco-Biology, Gui de Chauliac Hospital, Montpellier University Hospital, Montpellier, France.
  • Faculty of Medicine, University of Montpellier, Montpellier, France.
  • Laboratory of Medical Biology, Beziers Hospital, France.
  • CNRS UMR 9002, Institute of Human Genetics, Montpellier, France.
  • Institut Universitaire de France, Paris, France.

ORCID-Profile: Jérôme Moreaux, Caroline Bret

Förderung

  • Agence Nationale de la Recherche
  • Institut National Du Cancer
  • PLBIO22 PICASO
  • SIRIC Montpellier Cancer (INCa_Inserm_D-GOS_12553)
  • ARC foundation PGA EpiMM3D
  • Institut Carnot CALYM
  • Labex EpiGenMed
  • FFRMG (AAP-FFRMG-2021)

Zitieren

APA

Marianini, P., Lacheretz-Szablewski, V., Almeras, M., Moreaux, J., & Bret, C. (2024). CD38 , CD39 , and BCL2 differentiate disseminated forms of high‐grade B‐cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B‐cell lymphoma. Cytometry Part B: Clinical Cytometry, 106(6), 448-464. https://doi.org/10.1002/cyto.b.22208

Vancouver

Marianini P, Lacheretz-Szablewski V, Almeras M, Moreaux J, Bret C. CD38 , CD39 , and BCL2 differentiate disseminated forms of high‐grade B‐cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B‐cell lymphoma. Cytometry Part B: Clinical Cytometry. 2024;106(6):448-464. doi:10.1002/cyto.b.22208

BibTeX
@article{Marianini2024,
  author = {Marianini, Pauline and Lacheretz-Szablewski, Vanessa and Almeras, Marion and Moreaux, Jérôme and Bret, Caroline},
  title = {CD38 , CD39 , and BCL2 differentiate disseminated forms of high‐grade B‐cell lymphomas in biological fluids from Burkitt lymphoma and diffuse large B‐cell lymphoma},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2024},
  volume = {106},
  number = {6},
  pages = {448--464},
  doi = {10.1002/cyto.b.22208}
}
Kostenlos starten →